BR112022013865A2 - Métodos e composto - Google Patents
Métodos e compostoInfo
- Publication number
- BR112022013865A2 BR112022013865A2 BR112022013865A BR112022013865A BR112022013865A2 BR 112022013865 A2 BR112022013865 A2 BR 112022013865A2 BR 112022013865 A BR112022013865 A BR 112022013865A BR 112022013865 A BR112022013865 A BR 112022013865A BR 112022013865 A2 BR112022013865 A2 BR 112022013865A2
- Authority
- BR
- Brazil
- Prior art keywords
- methyl
- intermediates
- compound
- methods
- chroman
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Abstract
MÉTODOS E COMPOSTO. Esta revelação descreve um método e processo econômico e escalável para sintetizar o agente modulador do receptor sensível ao cálcio (CaSR) ácido 2-metil-5-((2R,4S)-2-((((R)-1-(naftalen-1-il)etil)amino)metil)croman-4-il)benzoico, seus intermediários e sais farmaceuticamente aceitáveis do mesmo. Também são descritos no presente documento usos dos ditos intermediários para a síntese de compostos que podem ser intermediários para a síntese de ácido 2-metil-5-((2R,4S)-2-((((R)-1-(naftalen-1-il)etil)amino)metil)croman-4-il)benzoico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202021002110 | 2020-01-17 | ||
PCT/IN2021/050045 WO2021144814A1 (en) | 2020-01-17 | 2021-01-17 | Methods, processes and intermediates for preparing chroman compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022013865A2 true BR112022013865A2 (pt) | 2022-09-13 |
Family
ID=74550720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022013865A BR112022013865A2 (pt) | 2020-01-17 | 2021-01-17 | Métodos e composto |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230140054A1 (pt) |
EP (1) | EP4090654A1 (pt) |
JP (1) | JP2023512918A (pt) |
CN (1) | CN114981253A (pt) |
AU (1) | AU2021207775A1 (pt) |
BR (1) | BR112022013865A2 (pt) |
CA (1) | CA3166512A1 (pt) |
MX (1) | MX2022008805A (pt) |
WO (1) | WO2021144814A1 (pt) |
ZA (1) | ZA202207850B (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113979982A (zh) * | 2021-11-03 | 2022-01-28 | 中国人民解放军空军军医大学 | 一种手性二氢色酮-2-羧酸类化合物及其衍生物的制备方法和应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5171865A (en) * | 1988-02-29 | 1992-12-15 | Sanwa Kagaku Kenkyusho Co., Ltd. | Process for the preparation of optically active 4-oxo-1-benzopyran-2-carboxylic acid derivatives and intermediates thereof |
FR2809396B1 (fr) * | 2000-05-24 | 2005-10-14 | Centre Nat Rech Scient | Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation |
FR2812875B1 (fr) | 2000-08-08 | 2003-12-12 | Centre Nat Rech Scient | Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation |
US7105537B2 (en) | 2003-01-28 | 2006-09-12 | Bristol-Myers Squibb Company | 2-substituted cyclic amines as calcium sensing receptor modulators |
EP1630157A4 (en) | 2003-05-28 | 2007-05-23 | Japan Tobacco Inc | ANTAGONIST OF CASR |
PT1882684E (pt) | 2005-05-19 | 2015-02-10 | Astellas Pharma Inc | Derivado de pirrolidina ou um seu sal |
CA2663436A1 (en) | 2006-10-04 | 2008-04-10 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
US8153658B2 (en) | 2006-11-16 | 2012-04-10 | Astellas Pharma, Inc. | Piperidine derivative or salt thereof |
BRPI0819799A2 (pt) | 2007-11-23 | 2015-05-26 | Leo Pharma As | Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença |
JP5685941B2 (ja) | 2008-10-03 | 2015-03-18 | 味の素株式会社 | CaSRアゴニスト |
WO2010042642A1 (en) | 2008-10-08 | 2010-04-15 | Amgen Inc. | Calcium receptor modulating agents |
CA2762137A1 (en) | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
WO2010150837A1 (ja) | 2009-06-25 | 2010-12-29 | 第一三共株式会社 | インドリン誘導体 |
RU2013128950A (ru) | 2010-11-26 | 2015-01-10 | Лео Фарма А/С | Замещенные циклопентилазины в качестве casr-активных соединений |
CN103270018A (zh) | 2010-11-26 | 2013-08-28 | 利奥制药有限公司 | 钙敏感受体激活化合物 |
WO2012069421A1 (en) | 2010-11-26 | 2012-05-31 | Leo Pharma A/S | Calcium-sensing receptor-active compounds |
AU2012226375B2 (en) | 2011-03-10 | 2017-04-13 | Lupin Atlantis Holdings Sa | Substituted morpholines as modulators for the calcium sensing receptor |
BR112013023914A2 (pt) | 2011-03-18 | 2016-12-13 | Lupin Ltd | derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio |
MX355670B (es) | 2012-02-24 | 2018-04-25 | Lupin Ltd | Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio. |
-
2021
- 2021-01-17 MX MX2022008805A patent/MX2022008805A/es unknown
- 2021-01-17 EP EP21703335.6A patent/EP4090654A1/en active Pending
- 2021-01-17 WO PCT/IN2021/050045 patent/WO2021144814A1/en unknown
- 2021-01-17 CA CA3166512A patent/CA3166512A1/en active Pending
- 2021-01-17 AU AU2021207775A patent/AU2021207775A1/en active Pending
- 2021-01-17 CN CN202180009700.5A patent/CN114981253A/zh active Pending
- 2021-01-17 US US17/792,298 patent/US20230140054A1/en active Pending
- 2021-01-17 BR BR112022013865A patent/BR112022013865A2/pt unknown
- 2021-01-17 JP JP2022543154A patent/JP2023512918A/ja active Pending
-
2022
- 2022-07-14 ZA ZA2022/07850A patent/ZA202207850B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021144814A1 (en) | 2021-07-22 |
ZA202207850B (en) | 2023-11-29 |
CA3166512A1 (en) | 2021-07-22 |
EP4090654A1 (en) | 2022-11-23 |
CN114981253A (zh) | 2022-08-30 |
US20230140054A1 (en) | 2023-05-04 |
JP2023512918A (ja) | 2023-03-30 |
AU2021207775A1 (en) | 2022-08-11 |
MX2022008805A (es) | 2022-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
BR0101241A (pt) | ácidos hidroxâmicos gem substituìdos | |
PE20121820A1 (es) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella | |
CY1108823T1 (el) | Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3 | |
BRPI0507903A (pt) | derivados de quinazolina e composição farmacêutica compreendendo os mesmos | |
AR065837A1 (es) | Composicion para el tratamiento del sindrome metabolico | |
PE20081563A1 (es) | Proceso para la preparacion de inhibidores de nep | |
BRPI0518360A2 (pt) | composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo | |
BR122012009534C8 (pt) | 4-[2-(4-metil-fenil-sulfanil)-fenil]-piperidina, seu uso e composição farmacêutica compreendendo o referido composto | |
BR112022013865A2 (pt) | Métodos e composto | |
BR112020012712A8 (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc | |
UY29919A1 (es) | Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones | |
AR070158A1 (es) | Compuesto de benzamida composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para antagonizar selectivamente los rceptores opioides kappa | |
NO20083836L (no) | N-hydroksyakrylamidforbindelser | |
BRPI1007404B8 (pt) | método para síntese de (1s,2r)-milnaciprano | |
BRPI0617655A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica | |
BR112022008786A2 (pt) | Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose | |
BRPI0416287A (pt) | compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização | |
BRPI0513857A (pt) | inibidores de hsp90 | |
BR9808758A (pt) | Derivados de cisteìna, processo para sua produção e farmacêuticos contendo os mesmos | |
BRPI0606881A2 (pt) | composto derivado de dihidroimidazotiazol, composição farmacêutica, seu uso e processo para a sua produção | |
BR112022008061A2 (pt) | Processo eficaz para síntese de 2-amino-5-cloro-n,3-dimetilbenzamida | |
BRPI0411308A (pt) | composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto | |
SV2005001805A (es) | 3-aminopirrolidinas como inhibidores de la captacion de monoamina ref. x-15735 | |
CL2009001150A1 (es) | Compuestos derivados de n-(2-amino-fenil)-acrilamidas, inhibidor de la histona-desacetilasa (hdac); procedimiento de preparacion; composicion faramceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |